Zobrazeno 1 - 10
of 38
pro vyhledávání: '"Greg Moeck"'
Autor:
Maria F. Mojica, Elise T. Zeiser, Scott A. Becka, David A. Six, Greg Moeck, Krisztina M. Papp-Wallace
Publikováno v:
Microbiology Spectrum, Vol 12, Iss 11 (2024)
ABSTRACT Taniborbactam (formerly VNRX-5133) is a novel, investigational boronic acid β-lactamase inhibitor. The combination of cefepime (FEP) with taniborbactam is active against Enterobacterales carrying class A, B, C, and/or D enzymes. We assessed
Externí odkaz:
https://doaj.org/article/a37186db696742128c58a99fe618b13a
Autor:
James A. Karlowsky, Meredith A. Hackel, Mark G. Wise, David A. Six, Tsuyoshi Uehara, Denis M. Daigle, Susan M. Cusick, Daniel C. Pevear, Greg Moeck, Daniel F. Sahm
Publikováno v:
Antimicrobial Agents and Chemotherapy. 67
Taniborbactam is a novel cyclic boronate β-lactamase inhibitor in clinical development in combination with cefepime. We assessed the in vitro activity of cefepime-taniborbactam and comparators against a 2018–2020 collection of Enterobacterales ( n
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2db316b6652ae028b33e829665b98779
https://doi.org/10.1128/aac.01281-22
https://doi.org/10.1128/aac.01281-22
Publikováno v:
Open Forum Infectious Diseases. 9
Background Cefepime-taniborbactam (FTB) combines cefepime (FEP), a fourth generation cephalosporin with taniborbactam, a novel inhibitor of metallo (MBL)- and serine β-lactamases (SBL). FTB 2.5g IV q8h was safe and effective in adults with complicat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ef15fc50becb9f0f890c59c9c0e9fa2d
https://doi.org/10.1093/ofid/ofac492.642
https://doi.org/10.1093/ofid/ofac492.642
Autor:
Paul C McGovern, Florian Wagenlehner, Leanne Gasink, Greg Moeck, Patrick L McLeroth, Mary Beth, Aaron Dane, Tim Henkel
Publikováno v:
Open Forum Infectious Diseases. 9
Background Carbapenem-resistant Enterobacterales and multidrug resistant Pseudomonas aeruginosa are global antimicrobial resistance threats. Cefepime-taniborbactam (FTB) is an investigational β-lactam/ β-lactamase inhibitor combination that is acti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::723ca35e57bb2a4899a5ba3baf454c7a
https://doi.org/10.1093/ofid/ofac492.022
https://doi.org/10.1093/ofid/ofac492.022
Autor:
James A. Karlowsky, Mark G. Wise, Meredith A. Hackel, Daniel C. Pevear, Greg Moeck, Daniel F. Sahm
Publikováno v:
Antimicrobial Agents and Chemotherapy. 66
Ceftibuten-ledaborbactam etzadroxil is a cephalosporin-boronate β-lactamase inhibitor prodrug combination under development as an oral treatment for complicated urinary tract infections caused by multidrug-resistant (MDR) Enterobacterales producing
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::73b6bc6b54bf8b87c1f6c07c78b4fa7c
https://doi.org/10.1128/aac.00934-22
https://doi.org/10.1128/aac.00934-22
Autor:
William J. Weiss, Christopher J. Burns, Randy W. Jackson, Greg Moeck, Eugen F. Mesaros, Jodie Hamrick, Susan M Cusick, Boyd Steven A, Bin Liu, Denis M. Daigle, Cassandra L Chatwin, Lisa McLaughlin, Kaitlyn John, Daniel C. Pevear, Allison L. Zulli, Robert E. Lee Trout, Luigi Xerri, Mark Pulse
Publikováno v:
Journal of Medicinal Chemistry
A major antimicrobial resistance mechanism in Gram-negative bacteria is the production of β-lactamase enzymes. The increasing emergence of β-lactamase-producing multi-drug-resistant “superbugs” has resulted in increases in costly hospital Emerg
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::516a17f5ca36ebed444b8e9c579d316c
https://doi.org/10.1021/acs.jmedchem.1c00437
https://doi.org/10.1021/acs.jmedchem.1c00437
Autor:
Andrew R Mack, Christopher Bethel, Steven Marshall, Robin Patel, David van Duin, Vance G Fowler, Daniel D Rhoads, Michael Jacobs, Focco van den Akker, David A Six, Greg Moeck, Krisztina M Papp-Wallace, Robert A Bonomo
Publikováno v:
Open Forum Infectious Diseases
Background Carbapenem resistance in Klebsiellae spp. arises through mutational and acquired mechanisms and is considered an “urgent threat” by the CDC. VNRX-5236 is a bicyclic boronate β-lactamase inhibitor (BLI) that combines oral bioavailabili
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d53d26d452359232a769ec0054cb5b1e
http://europepmc.org/articles/PMC8644492
http://europepmc.org/articles/PMC8644492
Autor:
Kaitlyn John, Jodie Hamrick, David A. Six, Denis M. Daigle, Tsuyoshi Uehara, Luigi Xerri, Susan M Cusick, Daniel C. Pevear, Manuela Benvenuti, Cassandra L Chatwin, Christopher J. Burns, Salvador Vernacchio, Randy W. Jackson, Greg Moeck, Bin Liu, Robert E. Lee Trout, Filomena De Luca, Jean Denis Docquier, Stefano Mangani, Cullen L. Myers, Cecilia Pozzi
As shifts in the epidemiology of β-lactamase-mediated resistance continue, carbapenem-resistant Enterobacterales (CRE) and carbapenem-resistant Pseudomonas aeruginosa (CRPA) are the most urgent threats. Although approved β-lactam (BL)-β-lactamase
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8ebef2baf47b65ca9a3ff1093605020a
http://hdl.handle.net/11365/1095652
http://hdl.handle.net/11365/1095652
Autor:
Jodie C, Hamrick, Jean-Denis, Docquier, Tsuyoshi, Uehara, Cullen L, Myers, David A, Six, Cassandra L, Chatwin, Kaitlyn J, John, Salvador F, Vernacchio, Susan M, Cusick, Robert E L, Trout, Cecilia, Pozzi, Filomena, De Luca, Manuela, Benvenuti, Stefano, Mangani, Bin, Liu, Randy W, Jackson, Greg, Moeck, Luigi, Xerri, Christopher J, Burns, Daniel C, Pevear, Denis M, Daigle
Publikováno v:
Antimicrobial Agents and Chemotherapy
As shifts in the epidemiology of β-lactamase-mediated resistance continue, carbapenem-resistant Enterobacterales (CRE) and carbapenem-resistant Pseudomonas aeruginosa (CRPA) are the most urgent threats.
As shifts in the epidemiology of β-lacta
As shifts in the epidemiology of β-lacta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::ee3c5227bd51a8f0a22f0a198deb9623
https://pubmed.ncbi.nlm.nih.gov/31871094
https://pubmed.ncbi.nlm.nih.gov/31871094
Autor:
Lisa McLaughlin, Salvador Vernacchio, Daniel C. Pevear, Greg Moeck, Lindsay M. Avery, Luigi Xerri
Publikováno v:
Open Forum Infectious Diseases
Background FEP-TAN (FTB) efficacy and safety are currently being evaluated in a Phase 3 trial (NCT03840148). TAN, a boronic acid-based β-lactamase inhibitor, restores susceptibility to FEP when resistance is driven by SBL or MBL (ie, NDM, VIM). This
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12b8c827378f3f226b86e276b3995017
http://europepmc.org/articles/PMC7776537
http://europepmc.org/articles/PMC7776537